Bank of New York Mellon’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Bank of New York Mellon’s Portfolio WX Stock Details WX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-13,759	Closed	-$595K	–	4434
2015 Q3	$595K	Sell	13,759 -481,695	-97%	-$20.3M	﹤0.01%	3505
2015 Q2	$20.9M	Sell	495,454 -518,130	-51%	-$21.9M	0.01%	1457
2015 Q1	$39.3M	Sell	1,013,584 -28,548	-3%	-$1.1M	0.01%	1037
2014 Q4	$35.1M	Buy	1,042,132 +65,861	+7%	+$2.33M	0.01%	1096
2014 Q3	$34.2M	Buy	976,271 +789,994	+424%	+$27.1M	0.01%	1102
2014 Q2	$6.12M	Sell	186,277 -1,042,839	-85%	-$35.7M	﹤0.01%	2212
2014 Q1	$45.3M	Sell	1,229,116 -440,564	-26%	-$16.2M	0.01%	950
2013 Q4	$64.1M	Buy	1,669,680 +77,075	+5%	+$2.43M	0.02%	748
2013 Q3	$43.6M	Sell	1,592,605 -280,265	-15%	-$6.64M	0.01%	945
2013 Q2	$39.3M	Buy	+1,872,870	New	+$36.6M	0.01%	971

Other funds holding WX

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

CCS

Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Bank of New York Mellon's WX Position: Q4 2015 in Review

Bank of New York Mellon sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 13,759 shares — an estimated $595K sold.

Bank of New York Mellon first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $64.1M in Q4 2013. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

Bank of New York Mellon reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
Bank of New York Mellon sold 13,759 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $595K.
Bank of New York Mellon first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
Bank of New York Mellon's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $64.1M in Q4 2013.
2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Bank of New York Mellon's 13F filing for Q4 2015, filed 12 Feb 2016.